Irinotecan Hydrochloride

• CAT Number: I000079
• CAS Number: 100286-90-6
• Molecular Formula: C₃₃H₃₈N₄O₆. HCl
• Molecular Weight: 623.14
• Purity: ≥95%
• Target: Topoisomerase I
• Solubility: DMSO: ≥ 51 mg/mL
• Storage: -20°C
• InChI: InChI=1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m0./s1
• InChIKey: GURKHSYORGJETM-WAQYZQTGSA-N
• SMILES: CCC1=C2C=C(C=CC2=NC3=C1CN4C3=CC5=C(C4=O)COC(=O)C5(CC)O)OC(=O)N6CCC(CC6)N7CCCCC7.Cl

Irinotecan hydrochloride (Cat.No:I000079) is a chemotherapeutic drug used for the treatment of various cancers, including colorectal cancer. It belongs to the class of topoisomerase I inhibitors and works by inhibiting DNA replication and inducing cell death. Irinotecan hydrochloride has shown efficacy in both advanced and metastatic cancer settings, often in combination with other chemotherapeutic agents.

Reference

[1]. Roy AC, Park SR, Cunningham D, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Feb 13 


[2]. JY Douillard, D Cunningham, AD Roth, M Navarro, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet, 2000, 355( 9209): 1041 – 1047. 


[3]. Prof Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. The Lancet, 1998, 352 ( 9138): 1407 – 1412. 


[4]. Armand JP, Ducreux M, Mahjoubi M et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1283-7.